Abstract 2327P
Background
Colorectal cancer (CRC) is a major public health issue, as it is amongst the most common forms of cancer incidence and mortality worldwide. Lately, intratutmoral cellular heterogeneity has been highlighted for survival and drug response evaluation. In 2015, the consensus molecular subtype system (CMS) surfaced as a potential diagnostic and prognostic tool for CRC. The CMS classification is based on gene expression profiles and recognizes four subtypes. Whereas CMS2/3 is characterized by high Wnt signaling, and Myc activity, CMS4 is defined by its TGF-β signaling, epithelial-mesenchymal transition (EMT), fibroblast accumulation, and overall worst prognosis. I examined the influence of the tumoral microenvironment on the intratumoral cellular heterogeneity of CRC.
Methods
Patient-derived organoids (PDO) model intratumoral heterogeneity of CRC effectively. PDOs were cultured from CRC surgical biopsy samples, and grown alone or with fibroblasts, in Matrigel or in collagen-enriched gel, with growth medium enriched or depleted from amino acids or glucose. The accumulation of collagen in the tumors is negatively correlated with patient survival. The expression levels of markers for CMS2/3 and CMS4 were evaluated with RT-qPCR, immunohistochemistry, and flow cytometry.
Results
We observed a higher rate of CRC cell positivity for CMS2/3 and CMS4 markers, along with their double positivity when co-cultured with fibroblasts. Similarly, the mixed phenotype positivity increased for CRC cells cultured in amino acid or glucose-free conditions compared to standard growth medium. In collagen, only the CMS4 marker positivity was higher compared to those in Matrigel. Furthermore, cocultured organoids demonstrated an increased positivity for the EMT markers.
Conclusions
Altering the microenvironment of CRC significantly modifies the intratumoral cellular heterogeneity, as collagen and fibroblast enrichment shifts the organoids to a CMS4 phenotype with partial EMT activity, both of which are suggestive of worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hungarian National Research, Development and Innovation Office & Hungarian Ministry of Innovation and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16